**Key Features & Benefits**

- **Enhanced Efficacy of Existing Antibiotics**: Enhances the susceptibility of multi-drug resistant *P. aeruginosa* to existing antibiotics such as colistin and polymyxin B.

- **Lower Doses and Reduced Side Effects**: By enhancing the effectiveness of CAPs, widens the therapeutic index by requiring lower dosages of the CAP, helping to minimize the side effects caused by CAPs.

- **Filling a Therapeutic Gap**: With no antibiotic adjuvant for CAPs currently approved for use, these small molecules offer a novel and much-needed therapeutic strategy for combating CAP-resistant strains.

**Potential Applications**

- Treating CAP-resistant strains of *P. aeruginosa*.

- Treating *P. aeruginosa* infections in patients experiencing side effects from large CAP doses.

- Can be developed into antibiotic adjuvants thereby enhancing effectiveness of existing antibiotics.

- Potential for use in other gram negative pathogens that utilize similar resistance mechanism.

- Infection prevention in vulnerable populations susceptible to *P. aeruginosa* and other bacterial infections.

*Fig. 1.* An adjuvant compound and colistin treatment in *Pseudomonas aeruginosa* resulted in enhanced antibiotic activity.